ImmuCell Corporation
ICCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $57 | $63 | $43 | $46 |
| - Cash | $3,886 | $6 | $5 | $4 |
| + Debt | $5,707 | $14 | $15 | $15 |
| Enterprise Value | $1,877 | $71 | $53 | $57 |
| Revenue | $6 | $6 | $8 | $8 |
| % Growth | -14.6% | -20.1% | 4.1% | – |
| Gross Profit | $2 | $3 | $3 | $3 |
| % Margin | 42.9% | 43.7% | 41.6% | 36.5% |
| EBITDA | $1 | $1 | $2 | $1 |
| % Margin | 9.9% | 20.1% | 27.8% | 17% |
| Net Income | -$0 | $1 | $1 | $1 |
| % Margin | -2.5% | 7.8% | 17.9% | 6.6% |
| EPS Diluted | -0.02 | 0.056 | 0.16 | 0.058 |
| % Growth | -136% | -65.3% | 177.8% | – |
| Operating Cash Flow | – | $2 | $2 | -$0 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | $1 | $1 | -$0 |